Sixteen startup teams pitched at the seventh annual — but first-ever virtual – Bayou Startup Showcase. Photo courtesy of OwlSpark and RED Labs

Even despite a global pandemic, two university-based summer startup accelerator programs were determined to continue on. And, that's exactly what they did.

University of Houston's RED Labs and Rice University's OwlSpark pivoted their summer program, which they put on collaboratively, to a virtual approach. On Thursday, August 6, the program's 16 startup teams pitched their projects at the seventh annual Bayou Startup Showcase.

Here are this year's Class 8 presentations:

EVA

Vascular access requires a medical team to use an ultrasound machine to help navigate a needle's precision during the procedure. However, 5 percent of procedures result in an inexact and painful outcome. OwlSpark company, EVA — which stands for Exact Vascular Access, has created a device that works with the ultrasound machine to endure navigation of the needle during the procedure.

CareSafe

Seven million people fall every year, but as great and helpful wearable devices are, they aren't foolproof. CareSafe, a RED Labs company, taps into home WiFi to visualize when a fall occurs and the company can even notify emergency contacts and emergency services.

Ai-Ris

People who live in underserved and rural areas don't have regular access to eye care — which means that these people are exposed to preventable eye diseases. Ai-Ris has created a portable, telemedicine-ready device that can help get these populations access to eye care.

Dividends360

Ninety million people invest in the stock market — and more than half of those investors are self directed and spending several hours a week on planning their investments. RED Labs company Dividends360 is a web-based platform to help the modern investor make his or her decisions in a more efficient way.

FirstGen Solutions

Expecting mothers can't take the majority of medications in the market because the effects of the chemicals on the unborn child is unknown, and testing is limited to costly, inaccurate, and highly regulated animal testing. FirstGen Solutions, an OwlSpark company, is producing a stem cell testing kit for pharmaceutical companies to use as an earlier and easier way to indicate potential risks a medicine could have.

nisa EFFECT

Women undergoing menopause have no control over their hot flashes, which can happen often, last up to 20 minutes, and be debilitating to daily activities. Nisa EFFECT has created a cooling bra so that the 80 percent of women who experience hot flashes during menopause can have a discrete way to cool down.

FreeFuse

Five hundred hours of video content is uploaded every minute, and the sheer oversaturation of the industry makes growing an audience extremely difficult for content producers. Interactive video platform FreeFuse, an OwlSpark company, wants to flip the script and allow content creators to see what its audient wants to see in terms of content.

Morpheus Health

Pharmaceutical companies don't make it easy to find out about side effects medicines can have on its users. Morpheus Health, an OwlSpark company, uses data and patient information to better customize and predict potential side effects a medicine can have. Morpheus's results don't replace prescriptions or doctor consultations, but instead allow the patient to take that information into the consultation room.

Phase Filter

​Changing the air filters is an easily forgotten chore that, if undone, can cause unnecessary air quality issues and a higher electricity bill for homeowners. Phase Filter has designed a self-scrolling air filter that's easy to install and only needs to be changed once a year,

Bloodhound

The OwlSpark and RED Labs summer programs are meant to help early-stage startups figure out their market need and determine whether or not their product is a viable business. The Bloodhound team explains how they came up with their idea for a software that helps detect bleed in surgeries, and then how they realized, after research and mentorship through the program, that it wasn't an idea worth pursuing. Doctors need more help with stopping bleeds than finding them.

Crew Trace Solutions

The Navy needs an upgrade to their accountability practice. That's where Crew Trace Solutions, an OwlSpark company run by two military veterans, comes in. The technology mirrors something like EZ-Tag where personnel onboard are tracked throughout the ship as they pass through sensors set up in doorways around the boat.

VAYL

Everyone dreads the discomfort and disappointment that usually comes with dental appointments. The oral hygiene tools on the market today aren't cutting it, says the VAYL team, a RED Labs company. VAYL has created a device that brushes the entire mouth in an optimal way for time and for cavity prevention.

MoodyCorium

Finding the right moisturizer is a costly and exhausting industry for women. MoodyCorium, an OwlSpark company, is working on a solution so that women can navigate the hundreds of products available on the market.

ElastEye

Half of the glaucoma patients could have had their disease prevented by better diagnostics — and that's exactly what ElastEye has developed. The RED Labs company has created a non-invasive, early detection device that determines the elasticity of the eye.

BitGrange

Supporting local farmers can be hard — it might raise the price of produce for consumers while orders tend to be smaller than farmers prefer. BItGrange, an OwlSpark company, created an e-commerce platform to allow consumers to go in on purchases together to create a win-win situation for both sides of the transaction.

dext

Simple daily tasks can be overwhelming to stroke survivors and the only solution is exercise and rehabilitation. Dext is a wearable tool to help take that exercise and rehab into a daily, easy to use setting.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.